A Comparison of the Pharmacokinetics and Pharmacodynamics of Pregabalin and Gabapentin

被引:0
|
作者
Howard N. Bockbrader
David Wesche
Raymond Miller
Sunny Chapel
Nancy Janiczek
Paula Burger
机构
[1] Pfizer Global Research & Development,
[2] Pfizer Global Research & Development,undefined
来源
Clinical Pharmacokinetics | 2010年 / 49卷
关键词
Neuropathic Pain; Gabapentin; Pregabalin; Postherpetic Neuralgia; Pain Score Reduction;
D O I
暂无
中图分类号
学科分类号
摘要
Pregabalin and gabapentin share a similar mechanism of action, inhibiting calcium influx and subsequent release of excitatory neurotransmitters; however, the compounds differ in their pharmacokinetic and pharmacodynamic characteristics. Gabapentin is absorbed slowly after oral administration, with maximum plasma concentrations attained within 3–4 hours. Orally administered gabapentin exhibits saturable absorption — a nonlinear (zero-order) process — making its pharmacokinetics less predictable. Plasma concentrations of gabapentin do not increase proportionally with increasing dose. In contrast, orally administered pregabalin is absorbed more rapidly, with maximum plasma concentrations attained within 1 hour. Absorption is linear (first order), with plasma concentrations increasing proportionately with increasing dose. The absolute bioavailability of gabapentin drops from 60% to 33% as the dosage increases from 900 to 3600 mg/day, while the absolute bioavailability of pregabalin remains at <-90% irrespective ofthe dosage. Both drugs can be given without regard to meals. Neither drug binds to plasma proteins. Neither drug is metabolized by nor inhibits hepatic enzymes that are responsible for the metabolism of other drugs. Both drugs are excreted renally, with elimination half-lives of approximately 6 hours.
引用
收藏
页码:661 / 669
页数:8
相关论文
共 50 条
  • [41] The pharmacokinetic properties of pregabalin and gabapentin: Differences and similarities
    Wesche, D.
    Bockbrader, H.
    EUROPEAN JOURNAL OF NEUROLOGY, 2005, 12 : 259 - 259
  • [42] Misuse and Abuse of Pregabalin and Gabapentin: Cause for Concern?
    Schifano, Fabrizio
    CNS DRUGS, 2014, 28 (06) : 491 - 496
  • [43] Replacement of Gabapentin with Pregabalin in Postherpetic Neuralgia Therapy
    Ifuku, Masataka
    Iseki, Masako
    Hidaka, Ikuhiro
    Morita, Yoshihito
    Komatus, Syuji
    Inada, Eiichi
    PAIN MEDICINE, 2011, 12 (07) : 1112 - 1116
  • [44] Replacement of gabapentin with pregabalin in postherpetic neuralgia therapy
    Loeser, John
    PAIN MANAGEMENT, 2011, 1 (06) : 503 - +
  • [46] Gabapentin to Pregabalin Therapy Transition: A Pharmacokinetic Simulation
    Bockbrader, Howard N.
    Budhwani, Meeta N.
    Wesche, David L.
    AMERICAN JOURNAL OF THERAPEUTICS, 2013, 20 (01) : 32 - 36
  • [47] Do gabapentin or pregabalin directly modulate the μ receptor?
    Manandhar, Preeti
    Murnion, Bridin Patricia
    Grimsey, Natasha L.
    Connor, Mark
    Santiago, Marina
    PEERJ, 2021, 9
  • [48] Pharmacokinetic properties of pregabalin and gabapentin: Differences and similarities
    Wesche, D
    Bockbrader, H
    EPILEPSIA, 2005, 46 : 280 - 281
  • [49] Misuse and Abuse of Pregabalin and Gabapentin: Cause for Concern?
    Fabrizio Schifano
    CNS Drugs, 2014, 28 : 491 - 496
  • [50] FROM THE FRONTLINE Bad medicine: gabapentin and pregabalin
    Spence, Des
    BMJ-BRITISH MEDICAL JOURNAL, 2013, 347